Do analysts rate LTY or APS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liberty Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aptose Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, LTY or APS?

Liberty Biopharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liberty Biopharma N/A N/A N/A -C$0.16 N/A Aptose Biosciences N/A N/A -C$154.69M -C$10.41 N/A

Is LTY or APS more profitable?

Aptose Biosciences' return on equity of 115.24% beat Liberty Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Liberty Biopharma N/A N/A N/A Aptose Biosciences N/A 115.24% -136.29%

Do analysts prefer APS or ACST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptose Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Acasti Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer APS or REUN?

Given Reunion Neuroscience's higher possible upside, analysts plainly believe Reunion Neuroscience is more favorable than Aptose Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptose Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Reunion Neuroscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is APS or REUN more profitable?

Aptose Biosciences' return on equity of 115.24% beat Reunion Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Aptose Biosciences N/A 115.24% -136.29% Reunion Neuroscience N/A -86.35% -26.50%

Do analysts rate NEPT or APS?

Given Neptune Wellness Solutions' higher probable upside, analysts clearly believe Neptune Wellness Solutions is more favorable than Aptose Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neptune Wellness Solutions 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aptose Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NEPT or APS more profitable?

Aptose Biosciences' return on equity of 115.24% beat Neptune Wellness Solutions' return on equity. Company Net Margins Return on Equity Return on Assets Neptune Wellness Solutions N/A N/A N/A Aptose Biosciences N/A 115.24% -136.29%

Do analysts rate APS or ATE?

Given Antibe Therapeutics' higher possible upside, analysts plainly believe Antibe Therapeutics is more favorable than Aptose Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptose Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Antibe Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is APS or ATE more profitable?

Aptose Biosciences' return on equity of 115.24% beat Antibe Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptose Biosciences N/A 115.24% -136.29% Antibe Therapeutics N/A -52.72% -19.13%

Aptose Biosciences (APS) Competitors

C$2.40 0.00 (0.00%)

As of 07/3/2026 03:46 PM Eastern

Compare

APS vs. LTY, ACST, REUN, NEPT, and ATE

Should you buy Aptose Biosciences stock or one of its competitors? MarketBeat compares Aptose Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptose Biosciences include Liberty Biopharma (LTY), Acasti Pharma (ACST), Reunion Neuroscience (REUN), Neptune Wellness Solutions (NEPT), and Antibe Therapeutics (ATE). These companies are all part of the "biotechnology" industry.

How does Aptose Biosciences compare to Liberty Biopharma?

Liberty Biopharma (CVE:LTY) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Aptose Biosciences' return on equity of 115.24% beat Liberty Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liberty Biopharma	N/A	N/A	N/A
Aptose Biosciences	N/A	115.24%	-136.29%

Liberty Biopharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liberty Biopharma	N/A	N/A	N/A	-C$0.16	N/A
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A

In the previous week, Liberty Biopharma had 1 more articles in the media than Aptose Biosciences. MarketBeat recorded 1 mentions for Liberty Biopharma and 0 mentions for Aptose Biosciences. Liberty Biopharma's average media sentiment score of 0.67 beat Aptose Biosciences' score of 0.00 indicating that Liberty Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liberty Biopharma	Positive
Aptose Biosciences	Neutral

0.0% of Aptose Biosciences shares are owned by institutional investors. 17.1% of Aptose Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liberty Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aptose Biosciences beats Liberty Biopharma on 5 of the 9 factors compared between the two stocks.

How does Aptose Biosciences compare to Acasti Pharma?

Aptose Biosciences (TSE:APS) and Acasti Pharma (CVE:ACST) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acasti Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Acasti Pharma has higher revenue and earnings than Aptose Biosciences. Acasti Pharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A
Acasti Pharma	C$2.71M	6.71	-C$10.54M	-C$0.48	N/A

In the previous week, Aptose Biosciences' average media sentiment score of 0.00 equaled Acasti Pharma'saverage media sentiment score.

Company	Overall Sentiment
Aptose Biosciences	Neutral
Acasti Pharma	Neutral

0.0% of Aptose Biosciences shares are held by institutional investors. Comparatively, 0.1% of Acasti Pharma shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by company insiders. Comparatively, 20.3% of Acasti Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aptose Biosciences has a beta of -1.288265, indicating that its share price is 229% less volatile than the broader market. Comparatively, Acasti Pharma has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Aptose Biosciences has a net margin of 0.00% compared to Acasti Pharma's net margin of -455.58%. Aptose Biosciences' return on equity of 115.24% beat Acasti Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	115.24%	-136.29%
Acasti Pharma	-455.58%	-67.58%	-8.25%

Summary

Acasti Pharma beats Aptose Biosciences on 7 of the 11 factors compared between the two stocks.

How does Aptose Biosciences compare to Reunion Neuroscience?

Aptose Biosciences (TSE:APS) and Reunion Neuroscience (TSE:REUN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Reunion Neuroscience has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Reunion Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A
Reunion Neuroscience	C$4.86M	0.00	-C$38.10M	-C$3.30	N/A

Given Reunion Neuroscience's higher possible upside, analysts plainly believe Reunion Neuroscience is more favorable than Aptose Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Reunion Neuroscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aptose Biosciences' return on equity of 115.24% beat Reunion Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	115.24%	-136.29%
Reunion Neuroscience	N/A	-86.35%	-26.50%

Aptose Biosciences has a beta of -1.288265, indicating that its share price is 229% less volatile than the broader market. Comparatively, Reunion Neuroscience has a beta of 4.2, indicating that its share price is 320% more volatile than the broader market.

0.0% of Aptose Biosciences shares are held by institutional investors. Comparatively, 50.7% of Reunion Neuroscience shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by insiders. Comparatively, 34.4% of Reunion Neuroscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Aptose Biosciences' average media sentiment score of 0.00 equaled Reunion Neuroscience'saverage media sentiment score.

Company	Overall Sentiment
Aptose Biosciences	Neutral
Reunion Neuroscience	Neutral

Summary

Reunion Neuroscience beats Aptose Biosciences on 8 of the 11 factors compared between the two stocks.

How does Aptose Biosciences compare to Neptune Wellness Solutions?

Neptune Wellness Solutions (TSE:NEPT) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Neptune Wellness Solutions' average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.

Company	Overall Sentiment
Neptune Wellness Solutions	Neutral
Aptose Biosciences	Neutral

0.0% of Aptose Biosciences shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aptose Biosciences has lower revenue, but higher earnings than Neptune Wellness Solutions. Aptose Biosciences is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neptune Wellness Solutions	C$48.80M	0.00	-C$192.95M	-C$24.16	N/A
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A

Given Neptune Wellness Solutions' higher probable upside, analysts clearly believe Neptune Wellness Solutions is more favorable than Aptose Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neptune Wellness Solutions	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aptose Biosciences' return on equity of 115.24% beat Neptune Wellness Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neptune Wellness Solutions	N/A	N/A	N/A
Aptose Biosciences	N/A	115.24%	-136.29%

Summary

Aptose Biosciences beats Neptune Wellness Solutions on 6 of the 10 factors compared between the two stocks.

How does Aptose Biosciences compare to Antibe Therapeutics?

Aptose Biosciences (TSE:APS) and Antibe Therapeutics (TSE:ATE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

0.0% of Aptose Biosciences shares are owned by institutional investors. 17.1% of Aptose Biosciences shares are owned by company insiders. Comparatively, 7.9% of Antibe Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aptose Biosciences has a beta of -1.288265, indicating that its share price is 229% less volatile than the broader market. Comparatively, Antibe Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

Antibe Therapeutics has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A
Antibe Therapeutics	C$9.71M	0.00	-C$18.24M	-C$0.35	N/A

Aptose Biosciences' return on equity of 115.24% beat Antibe Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	115.24%	-136.29%
Antibe Therapeutics	N/A	-52.72%	-19.13%

In the previous week, Aptose Biosciences' average media sentiment score of 0.00 equaled Antibe Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aptose Biosciences	Neutral
Antibe Therapeutics	Neutral

Given Antibe Therapeutics' higher possible upside, analysts plainly believe Antibe Therapeutics is more favorable than Aptose Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Antibe Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Antibe Therapeutics beats Aptose Biosciences on 6 of the 11 factors compared between the two stocks.

Get Aptose Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APS vs. The Competition

Export

Metric	Aptose Biosciences	Biotechnology Industry	Medical Sector	TSE Exchange
Market Cap	C$6.13M	C$516.65M	C$7.18B	C$13.07B
Dividend Yield	0.39%	3.88%	2.66%	6.18%
P/E Ratio	-0.23	3.09	28.02	36.51
Price / Sales	N/A	6,669.11	538.82	10.34
Price / Cash	1.60	13.13	49.26	82.29
Price / Book	-0.18	88.67	10.96	4.52
Net Income	-C$154.69M	-C$96.07M	C$3.57B	C$299.09M
7 Day Performance	6.67%	0.17%	2.12%	1.85%
1 Month Performance	9.09%	2.10%	5.25%	1.71%
1 Year Performance	98.35%	68.02%	33.29%	36.40%

Aptose Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APS Aptose Biosciences	N/A	C$2.40 flat	N/A	+98.3%	C$6.13M	N/A	N/A	31
LTY Liberty Biopharma	N/A	C$2.00 +∞	N/A	+0.0%	C$21.54M	N/A	N/A	N/A	News Coverage Gap Up
ACST Acasti Pharma	N/A	C$0.58 +1.8%	N/A	+0.0%	C$18.19M	C$2.71M	N/A	32
REUN Reunion Neuroscience	N/A	N/A	N/A	N/A	C$16.64M	C$4.86M	N/A	190	Gap Down
NEPT Neptune Wellness Solutions	N/A	N/A	N/A	N/A	C$15.73M	C$48.80M	N/A	130	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:APS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptose Biosciences (APS) Competitors

APS vs. LTY, ACST, REUN, NEPT, and ATE

How does Aptose Biosciences compare to Liberty Biopharma?

Summary

How does Aptose Biosciences compare to Acasti Pharma?

Summary

How does Aptose Biosciences compare to Reunion Neuroscience?

Summary

How does Aptose Biosciences compare to Neptune Wellness Solutions?

Summary

How does Aptose Biosciences compare to Antibe Therapeutics?

Summary

Media Sentiment Over Time

APS vs. The Competition

Aptose Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptose Biosciences (APS) Competitors

APS vs. LTY, ACST, REUN, NEPT, and ATE

How does Aptose Biosciences compare to Liberty Biopharma?

Is LTY or APS more profitable?

Which has better earnings and valuation, LTY or APS?

Does the media refer more to LTY or APS?

Do institutionals and insiders believe in LTY or APS?

Do analysts rate LTY or APS?

Summary

How does Aptose Biosciences compare to Acasti Pharma?

Do analysts prefer APS or ACST?

Which has stronger valuation and earnings, APS or ACST?

Does the media refer more to APS or ACST?

Do insiders & institutionals have more ownership in APS or ACST?

Which has more risk & volatility, APS or ACST?

Is APS or ACST more profitable?

Summary

How does Aptose Biosciences compare to Reunion Neuroscience?

Which has better earnings & valuation, APS or REUN?

Do analysts prefer APS or REUN?

Is APS or REUN more profitable?

Which has more volatility & risk, APS or REUN?

Do institutionals and insiders have more ownership in APS or REUN?

Does the media refer more to APS or REUN?

Summary

How does Aptose Biosciences compare to Neptune Wellness Solutions?

Does the media favor NEPT or APS?

Do insiders & institutionals hold more shares of NEPT or APS?

Which has better valuation and earnings, NEPT or APS?

Do analysts rate NEPT or APS?

Is NEPT or APS more profitable?

Summary

How does Aptose Biosciences compare to Antibe Therapeutics?

Do insiders and institutionals have more ownership in APS or ATE?

Which has more volatility & risk, APS or ATE?

Which has better valuation and earnings, APS or ATE?

Is APS or ATE more profitable?

Does the media prefer APS or ATE?

Do analysts rate APS or ATE?

Summary

Media Sentiment Over Time

APS vs. The Competition

Aptose Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools